Apr 11, 2020

CSL Behring and Takeda Pharmaceutical Are Leading a Coalition to Develop a COVID-19 Hyperimmune Therapy

Posted by in category: biotech/medical

Collaboration will always accelerate society faster than competition ever will:


“Biotest, BPL, LFB, and Octapharma have joined an alliance formed by CSL Behring (ASX: CSL/USOTC: CSLLY) and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE: TAK) to develop a potential plasma-derived therapy for treating COVID-19. The alliance will begin immediately with the investigational development of one, unbranded anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin medicine with the potential to treat individuals with serious complications from COVID-19.”

Six companies will work together to develop a plasma-derived antibody product to fight SARS-CoV-2.

Comments are closed.